Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Verastem (VSTM)
NASDAQ:VSTM
Holding VSTM?
Track your performance easily
VSTM Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.60 - $14.22
Previous Close$3.36
Volume386.26K
Average Volume (3M)877.17K
Market Cap
$85.09M
Enterprise Value$17.25M
Total Cash (Recent Filing)$110.13M
Total Debt (Recent Filing)$42.28M
Price to Earnings (P/E)―
Beta2.00
Next Earnings
Jul 31, 2024EPS Estimate
-$0.99Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.40
Shares Outstanding25,325,551
10 Day Avg. Volume547,647
30 Day Avg. Volume877,170
Standard Deviation0.32
R-Squared0.00186
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)0.77
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.19
Forecast
1Y Price Target
$20.08Price Target Upside495.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Verastem News
PremiumCompany Announcements
Verastem Advances Cancer Treatment with Promising Trial Results
Bulls Say, Bears Say
Bulls Say
Efficacy And Safety DataThe company's poster presenter highlighted an impressive 83% overall response rate (ORR), significantly higher than the standard of care.
Market OpportunityThe potential to address a large market opportunity in pancreatic cancer is significant, with an estimated 66,000 patients expected to be diagnosed.
New Drug ApplicationThe initiation of a rolling New Drug Application for lead asset avutometinib and defactinib in low grade serous ovarian cancer has been announced.
Bears Say
Clinical TrialsDisappointment is expressed regarding the lower overall response rate in the RAMP 201 study compared to previously reported data.
Financial PerformanceVerastem reported no revenues and a net loss of $1.26 per share, compared to consensus estimated net loss of $1.06 per share.
Safety IssuesConcerns around potential safety issues seen for avutometinib and defactinib in the RAMP 205 study are noted.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
VSTM FAQ
What was Verastem’s price range in the past 12 months?
Verastem lowest stock price was $2.60 and its highest was $14.22 in the past 12 months.
What is Verastem’s market cap?
Currently, no data Available
When is Verastem’s upcoming earnings report date?
Verastem’s upcoming earnings report date is Jul 31, 2024 which is 109 days ago.
How were Verastem’s earnings last quarter?
Verastem released its earnings results on May 09, 2024. The company reported -$1.26 earnings per share for the quarter, missing the consensus estimate of -$1.031 by -$0.229.
Is Verastem overvalued?
According to Wall Street analysts Verastem’s price is currently Undervalued.
Does Verastem pay dividends?
Verastem does not currently pay dividends.
What is Verastem’s EPS estimate?
Verastem’s EPS estimate is -$0.99.
How many shares outstanding does Verastem have?
Verastem has 25,325,550 shares outstanding.
What happened to Verastem’s price movement after its last earnings report?
Verastem reported an EPS of -$1.26 in its last earnings report, missing expectations of -$1.031. Following the earnings report the stock price went down -0.587%.
Which hedge fund is a major shareholder of Verastem?
Among the largest hedge funds holding Verastem’s share is Viking Global Investors LP. It holds Verastem’s shares valued at 29M.
---
Verastem Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$20.08 (495.85% Upside)
$20.08 (495.85% Upside)
Blogger Sentiment
Bullish
VSTM Sentiment 100%
Sector Average 71%
Sector Average 71%
Insider Transactions
Sold Shares
Worth $6.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 6.5%
Last 30 Days ▲ 2.8%
Last 30 Days ▲ 2.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-62.87%
12-Months-Change
Fundamentals
Return on Equity
-210.18%
Trailing 12-Months
Asset Growth
2.20%
Trailing 12-Months
Company Description
Verastem
Verastem, Inc., operating as Verastem Oncology, is a biopharmaceutical company focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients. It markets COPIKTRA™ (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K) and dual inhibitor of PI3K-delta and PI3K-gamma, which is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies. The indication in FL is approved under accelerated approval based on overall response rate. In addition, it is developing the focal adhesion kinase inhibitor defactinib, which is being evaluated in three separate clinical collaborations in combination with immunotherapeutic agents for the treatment of various different cancer types, including pancreatic cancer, ovarian cancer, non-small cell lung cancer (NSCLC), and mesothelioma. Verastem, Inc. has collaboration agreements with Yakult Honsha Co., Ltd., CSPS Pharmaceutical Group Limited and The Leukemia & Lymphoma Society. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.
---
VSTM Stock 12 Month Forecast
Average Price Target
$20.08
▲(495.85% Upside)
Technical Analysis
Corvus Pharmaceuticals
―
Daré Bioscience
―
Rhythm Pharmaceuticals
―
Revance Therapeutics
―
Best Analysts Covering VSTM
1 Year
1 Year Success Rate
5/14 ratings generated profit
1 Year Average Return
-4.34%
reiterated a buy rating 6 months ago
Copying Gregory Renza's trades and holding each position for 1 Year would result in 35.71% of your transactions generating a profit, with an average return of -4.34% per trade.
---